|Articles|September 26, 2022
How Sponsors and CROs can Fully Benefit from the Permanent Shift Toward Decentralized Clinical Trials Brought About by the COVID-19 Pandemic
Author(s)PCM Trials
There is a growing body of evidence that hybrid and decentralized clinical trials are here to stay. What was once a nice-to-have is quickly transforming into a must-have. The catalyst for this dramatic shift was the COVID-19 pandemic. To aid sponsors and CROs in fully realizing the benefits of decentralized clinical trial methods moving forward, this whitepaper extracts the lessons learned from the pandemic and their implications for clinical trials now and in the future.
Trending on Applied Clinical Trials Online
1
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
2
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
3
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
4
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
5